— Arcadia revenues increase 11% year over year driven by 24% growth in Zola® — — Arcadia receives 2.7 million shares of stock in ABVE — — Arcadia eliminates $1M in liabilities — DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. “We are very pleased with our performance for the second quarter of 2025,” said T.J. Schaefer, CEO of Arcadia. “While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once again surpassed the performance of the category. Our gross margins have now exceeded 30% for ten straight quarters, while our underlying operating...

Operating cash flow grew 22% in the first half of the year Company reaffirms projected 2025 revenue of $30–35 million and 28% EBITDA margin Conference call today at 5:00 pm ET to discuss results DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial intelligence solutions, today announced its financial results for the three months ended June 30, 2025. Second quarter revenue declined year over year from $3.6 million to $3.0 million due to timing effects from Indonesia and a commercial contract. The Company generated $2.1 million of operating cash flow during the quarter compared with a use of $500 thousand in the second quarter of 2024. Operating cash flow for the six months ended June 30, 2025 of $1.4 million increased 22% over the...

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM), (the “Company”), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation, energy security and smart city infrastructure, today announced its second quarter results for the period ended June 30, 2025. Financial Highlights12% Revenue increase from Q1 2025 to Q2 2025 60% of Revenues from Non-Government Commercial Entities YTD June 30, 2025 37% of revenues from International operations YTD June 30, 2025 Positive GAAP Gross Margin 20% for Q2 2025, a 4-percentage point increase over Q2 2024 Adjusted non-GAAP Gross Margin, net of non-cash costs 30% for Q2 2025, a 12-percentage point increase over Q2 2024 Operating costs reduced by $1.2 million in Q2 2025 compared to Q2 2024 Backlog of $7M Debt free and...

FREMONT, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today reported financial results for the second quarter ended June 30, 2025. “We navigated a dynamic market environment in the second quarter, while laying the groundwork for improved growth ahead, primarily in our Federal and Military verticals where we are awaiting sizeable business that was delayed in Q2 and is expected in Q3. In addition, we have accelerated and expanded our MDU market penetration efforts in more countries and more verticals,”, said Tuvia Barlev, Chairman and CEO of Actelis. “We grew 31% in revenues sequentially vs. Q1 and we are executing multiple comprehensive...

– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine’s path to approval for schizophrenia in Q4 2025; potential NDA submission targeted for Q2 2026 – CUPERTINO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in...

Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2025 operating and financial results and reviewed recent business highlights. “We are proud to enter the second half of the year with strong momentum as we have achieved all of our key milestones to date including advancing tegoprubart in kidney, islet cell (type 1 diabetes), and liver allotransplantation, as well as in xenotransplantation....

HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) —  KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a Bitcoin-Plus Treasury company that builds a portfolio of frontier technology businesses ranging from high performance energy systems to AI Robotics, today reported results for the second quarter ended June 30, 2025. “KULR is in its strongest financial position to accelerate its growth and continue its innovations,” commented KULR CEO Michael Mo. “Alongside the increased revenue in Q2, our Bitcoin holdings provide a solid financial balance sheet that enables us to invest confidently in developing new KULR ONE battery products, expand our R&D efforts, and drive towards the next phase of our growth.” Second Quarter 2025 Financial Results Revenues: In the second quarter...

SAN JOSE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended June 30, 2025. As of June 30, 2025, the Fund’s net assets were approximately $0.7 million, or $0.11 per share, compared with net assets of approximately $0.8 million, or $0.12 per share as of March 31, 2025. As of June 30, 2025, the Fund’s portfolio included public and private securities valued at approximately $0.7 million, or $0.10 per share, which includes approximately $0.07 per share in cash and cash equivalents. Portfolio Summary (as of 6/30/25)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $0.22 million $0.03Cash/Cash Equivalents $0.51...

280% increase in quarterly revenue with a strong start in its energy services and edge computing businesses puts the Company on plan to achieve guidance of $28M to $30M for the full year JACKSONVILLE, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), a provider of adaptive, versatile and streamlined Edge Data Center (“EDC”) solutions and operational services for the deployment of “behind the meter” electrical power reported financial results for the second quarter (“Q2 2025”) ended June 30, 2025. In addition to the equivalent quarter revenue growth, consecutive quarterly revenue growth was more than 16% for a total of $10.7 million for the first six months, the highest revenue for that period in the Company’s history.Second Quarter 2025 and Recent Operational...

Expands senior leadership team and board of directors to support next phase of growth ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, “We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management. Equally important, we have significantly strengthened our...